98%
921
2 minutes
20
Purpose: Both breast reduction surgery (BRS) in adolescent girls and chest masculinization surgery (CMS) transgender and nonbinary (TGNB) individuals improve physical discomfort and psychological well-being. Nonetheless, CMS in adolescents is highly contested due to concerns regarding safety and capacity for consent. Here, we compare both procedures to quantify trends in incidence, minimum age, and surgical outcomes.
Methods: The National Surgical Quality Improvement Program database was queried from 2018 to 2021 for cisgender and TGNB adolescents 18 years or younger who underwent BRS or CMS. Our primary outcome was the incidence of postoperative complications within 30 days of surgery. Multivariate logistic regression was performed to determine if CMS was associated with postoperative complications.
Results: Of 2504 adolescents, the majority (n = 2186 [87.3%]) were cisgender female patients who underwent BRS, compared with TGNB adolescents (n = 318 [12.7%]) who underwent CMS. BRS patients were younger at time of surgery (mean [SD] 16.7 [1.2], 17.5 [0.9]; P < 0.001). The minimum age for BRS was consistently 2 to 3 years younger than that for CMS (12.1 to 12.6 years vs 14.0 to 15.1 years). A comparable frequency of BRS and CMS patients developed 1 or more complications within 30 days of surgery (n = 98 [4.5%], n = 13 [4.1%]; P = 0.775).
Conclusion: Cisgender female adolescents undergo breast surgery at a 7-fold rate compared with TGNB adolescents and do so at significantly younger ages. Given the favorable effects of BRS and CMS on psychosocial well-being and their comparable surgical risk of complications, our data help recontextualize the concerns surrounding adolescent CMS.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1097/SAP.0000000000003981 | DOI Listing |
Int J Equity Health
July 2025
National Health School, Carlos III Health Institute, Madrid, Spain.
Background: HIV continues to be a global public health challenge, especially in transgender and non-binary people (TGNB). Despite the high effectiveness of Pre-Exposure Prophylaxis (PrEP) and Post-Exposure Prophylaxis (PEP) in reducing HIV transmission, their implementation in this population is unknown. This study describes PrEP and PEP awareness, knowledge of how to access, and use and identifies the factors associated among the TGNB population living in Spain.
View Article and Find Full Text PDFEpidemiol Health
August 2025
Department of Environmental Health Sciences, Graduate School of Public Health, Seoul National University, Seoul, Korea.
Objectives: Understanding the experiences of transgender and non-binary (TGNB) individuals from a life-course perspective is essential. This article aims to identify ages at key milestones related to transgender identity and assess experiences of stigmatization among TGNB individuals across different life stages.
Methods: We analyzed data from a nationwide longitudinal survey of 585 TGNB adults in Korea collected in 2020 and 2021.
Perspect Sex Reprod Health
June 2025
Center for Urogynecology and Pelvic Reconstructive Surgery; Women's Health Institute, Cleveland Clinic, Cleveland, Ohio, USA.
Context: Testosterone, which some transgender and non-binary (TGNB) individuals born with a uterus will use for gender affirmation, is not a form of contraception. Gaps remain in understanding how well clinicians address contraceptive needs with individuals initiating testosterone.
Methodology: This was an IRB-approved retrospective analysis of TGNB individuals on testosterone for gender affirmation.
Drug Alcohol Rev
July 2025
Department of Psychology, University of Illinois, Champaign-Urbana, Illinois, USA.
Introduction: This study examined an intersectional perspective on alcohol use disparities within transgender and nonbinary (TGNB) adults.
Methods: We examined the data from the 2015 U.S.
J Sex Med
May 2025
Department of Urology, University of California, San Diego Health, San Diego, CA 92103, United States.
Background: Gender-affirming medical therapy (GAMT), including puberty blockers (PB) and gender-affirming hormone therapy (GAHT), is part of the transition for many transgender and nonbinary (TGNB) individuals; however, there have been few studies investigating sexual function and desire during GAMT, and no reports on individuals who received PB.
Aim: We aimed to qualitatively evaluate the sexual experience of TGNB individuals during GAMT and identify significant and consistent themes that arose from our analysis.
Methods: We performed an Institutional Review Board-approved two-institutional study.